BIO-PATH HOLDINGS, INC. Financials
Quarterly XBRL submissions from SEC 10-K and 10-Q filings.
Income Statement (Last 8 Quarters)
(2)| Period | Revenue | YoY % | Net Income | YoY % | Operating Income | EPS |
|---|---|---|---|---|---|---|
| Q2 FY202510-Q · 2025-06-30 | — | — | -$4.6M | — | -$4.6M | -$0.55 |
| Q1 FY202510-Q · 2025-03-31 | — | — | -$2.9M | — | -$3.2M | -$0.40 |
Balance Sheet
| Period | Total Assets | Total Liabilities | Cash & Equivalents | Shareholders Equity |
|---|---|---|---|---|
| Q2 FY202510-Q | $746.0K | $7.9M | — | -$7.2M |
| Q1 FY202510-Q | $2.2M | $4.8M | — | -$2.6M |
Cash Flow Highlights
| Period | Operating Income | Net Income | Gross Profit | Shares Outstanding |
|---|---|---|---|---|
| Q2 FY202510-Q | -$4.6M | -$4.6M | — | 8,307,892 |
| Q1 FY202510-Q | -$3.2M | -$2.9M | — | 8,307,892 |
Filings
(3)Methodology
Every figure on this page is pulled directly from BIO-PATH HOLDINGS, INC.'s own XBRL submissions to the U.S. Securities and Exchange Commission. XBRL is the standardized tagging format the SEC requires for line items in 10-K and 10-Q filings, which means revenue, net income, and balance-sheet entries are reported by the company itself — not estimated by us.
Cayman Journal reconciles preferred GAAP tags (for example, Revenues, RevenueFromContractWithCustomerExcludingAssessedTax) and normalizes them so quarter-over-quarter comparability is preserved. Our automated ingestion runs nightly; markets editors spot-check flagged anomalies before they appear on the public hub. Where a tag is missing for a given period, we surface an em dash rather than impute a value.
Source documents are linked under Filings above and point to the original EDGAR submission index. Errors should be reported to [email protected].